Aurinia Provides Update on Proxy Statement
Aurinia Pharmaceuticals (NASDAQ: AUPH) has filed a supplement to its Proxy Statement dated June 3, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
The purpose of the Supplement is to reduce the proposed increase in the shares reserved for issuance under the Company’s Equity Incentive Plan in Proposal 4 from 11,375,000 Plan Shares (as defined in the Proxy Statement/Circular) to 8,500,000 Plan Shares. Accordingly, the Supplement revises and amends the Proxy Statement/Circular to decrease the number of Plan Shares requested to be reserved for use under the Company’s Equity Incentive Plan in Proposal 4 in the Proxy Statement/Circular from 35,190,115 to 32,315,115, representing a total increase of 8,500,000 Plan Shares, and representing, in aggregate,
A copy of the Supplement is available on the Company’s website at https://www.auriniapharma.com/investors-and-media/news-events/2024-agm, and on the Company’s profiles on EDGAR at www.sec.gov/EDGAR and SEDAR+ at www.sedarplus.ca.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603620342/en/
Media and Investor Inquiries:
Andrea Christopher
Corporate Communications and Investor Relations, Aurinia
achristopher@auriniapharma.com
ir@auriniapharma.com
Source: Aurinia Pharmaceuticals Inc.